---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037578"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:11:46.262699+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kymera Q2 net loss $38.8M; cash $472M; Sanofi to start KT-474 Phase 2 in Q4 2023

## Summary
- Collaboration revenue $16.5M (up from $11.5M YoY); R&D expense $45.8M; net loss narrowed to $38.8M.
- Cash & equivalents $472M as of June 30, 2023; cash runway into second half of 2025.
- Partner Sanofi plans Phase 2 trials for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in Q4 2023.
- Phase 1 data for KT-253 (MDM2), KT-333 (STAT3), KT-413 (IRAKIMiD) expected later in 2023.
- Appointed Jeremy Chadwick as COO and Justine Koenigsberg as VP, Head of IR.

## SEC filing metadata
- accession: 0000950170-23-037578
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000095017023037578/0000950170-23-037578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000095017023037578/kymr-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037578
- JSON: https://secwatch.observer/filing/0000950170-23-037578.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037578.txt

## Key facts
- Earnings Releases
  Kymera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $16.5 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $16.5 million
  - Result: reported results
  source text: . A replay of the webcast will be archived and available following the event. Second Quarter 2023 Financial Results Collaboration Revenues: Collaboration revenues were $16.5 million for the second quarter of 2023 compared to $11.5 million for the second quarter of 2022. Collaboration revenues include revenue from the Company’s Sanofi and Vertex
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000095017023037578/0000950170-23-037578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.